Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53


The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease.

Verbeke F, Siwy J, Van Biesen W, Mischak H, Pletinck A, Schepers E, Neirynck N, Magalhães P, Pejchinovski M, Pontillo C, Lichtinghagen R, Brand K, Vlahou A, De Bacquer D, Glorieux G.

Nephrol Dial Transplant. 2019 Dec 14. pii: gfz242. doi: 10.1093/ndt/gfz242. [Epub ahead of print]


Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy.

Siwy J, Ahonen L, Magalhães P, Frantzi M, Rossing P.

Methods Mol Biol. 2020;2067:287-306. doi: 10.1007/978-1-4939-9841-8_18.


A single-center study to evaluate the efficacy of a fetal urine peptide signature predicting postnatal renal outcome in fetuses with posterior urethral valves.

Buffin-Meyer B, Tkaczyk M, Stańczyk M, Breuil B, Siwy J, Szaflik K, Talar T, Wojtera J, Krzeszowski W, Decramer S, Klein J, Schanstra JP.

Pediatr Nephrol. 2020 Mar;35(3):469-475. doi: 10.1007/s00467-019-04390-9. Epub 2019 Nov 7.


Author Correction: Urinary CE-MS peptide marker pattern for detection of solid tumors.

Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V.

Sci Rep. 2019 Sep 3;9(1):12864. doi: 10.1038/s41598-019-49304-9.


Proteomics and personalized medicine: a focus on kidney disease.

Siwy J, Mischak H, Zürbig P.

Expert Rev Proteomics. 2019 Sep;16(9):773-782. doi: 10.1080/14789450.2019.1659138. Epub 2019 Aug 23.


Emerging urine-based proteomic biomarkers as valuable tools in the management of chronic kidney disease.

Zürbig P, Siwy J, Mischak H.

Expert Rev Mol Diagn. 2019 Oct;19(10):853-856. doi: 10.1080/14737159.2019.1657406. Epub 2019 Aug 21. No abstract available.


Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future.

Latosinska A, Siwy J, Mischak H, Frantzi M.

Electrophoresis. 2019 Sep;40(18-19):2294-2308. doi: 10.1002/elps.201900091. Epub 2019 May 14. Review.


Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial.

Siwy J, Klein T, Rosler M, von Eynatten M.

Proteomics Clin Appl. 2019 Mar;13(2):e1800144. doi: 10.1002/prca.201800144. Epub 2019 Jan 28.


Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study.

Weidemann F, Beer M, Kralewski M, Siwy J, Kampmann C.

Mol Genet Metab. 2019 Feb;126(2):169-182. doi: 10.1016/j.ymgme.2018.11.005. Epub 2018 Nov 12.


Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease.

Liu Y, Pejchinovski M, Wang X, Fu X, Castelletti D, Watnick TJ, Arcaro A, Siwy J, Mullen W, Mischak H, Serra AL.

Sci Rep. 2018 Apr 3;8(1):5584. doi: 10.1038/s41598-018-22938-x.


Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling.

Magalhães P, Pontillo C, Pejchinovski M, Siwy J, Krochmal M, Makridakis M, Carrick E, Klein J, Mullen W, Jankowski J, Vlahou A, Mischak H, Schanstra JP, Zürbig P, Pape L.

Proteomics Clin Appl. 2018 Sep;12(5):e1700163. doi: 10.1002/prca.201700163. Epub 2018 Apr 23.


Urinary CE-MS peptide marker pattern for detection of solid tumors.

Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V.

Sci Rep. 2018 Mar 27;8(1):5227. doi: 10.1038/s41598-018-23585-y. Erratum in: Sci Rep. 2019 Sep 3;9(1):12864.


Comparative proteome and peptidome analysis of the cephalic fluid secreted by Arapaima gigas (Teleostei: Osteoglossidae) during and outside parental care.

Torati LS, Migaud H, Doherty MK, Siwy J, Mullen W, Mesquita PEC, Albalat A.

PLoS One. 2017 Oct 24;12(10):e0186692. doi: 10.1371/journal.pone.0186692. eCollection 2017.


Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus.

Pejchinovski M, Siwy J, Mullen W, Mischak H, Petri MA, Burkly LC, Wei R.

Lupus. 2018 Jan;27(1):6-16. doi: 10.1177/0961203317707827. Epub 2017 May 5.


Polymerization-Incompetent Uromodulin in the Pregnant Stroke-Prone Spontaneously Hypertensive Rat.

Mary S, Small HY, Siwy J, Mullen W, Giri A, Delles C.

Hypertension. 2017 May;69(5):910-918. doi: 10.1161/HYPERTENSIONAHA.116.08826. Epub 2017 Mar 27.


Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology.

Wei R, Gao B, Shih F, Ranger A, Dearth A, Mischak H, Siwy J, Wisniacki N, Petri M, Burkly LC.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1468-1477. doi: 10.1093/ndt/gfw446.


[Proteome analysis of undiluted vitreous humor in patients with branch retinal vein occlusion].

Dacheva I, Reich M, Nobl M, Ceglowska K, Wasiak J, Siwy J, Zürbig P, Mischak H, Koch FHJ, Kopitz J, Kretz FTA, Tandogan T, Auffarth GU, Koss MJ.

Ophthalmologe. 2018 Mar;115(3):203-215. doi: 10.1007/s00347-017-0469-z. German.


Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis.

Siwy J, Zürbig P, Argiles A, Beige J, Haubitz M, Jankowski J, Julian BA, Linde PG, Marx D, Mischak H, Mullen W, Novak J, Ortiz A, Persson F, Pontillo C, Rossing P, Rupprecht H, Schanstra JP, Vlahou A, Vanholder R.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2079-2089. doi: 10.1093/ndt/gfw337.


Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice.

Klein J, Ramirez-Torres A, Ericsson A, Huang Y, Breuil B, Siwy J, Mischak H, Peng XR, Bascands JL, Schanstra JP.

Kidney Int. 2016 Nov;90(5):1045-1055. doi: 10.1016/j.kint.2016.06.023. Epub 2016 Aug 12.


A urinary proteome-based classifier for the early detection of decline in glomerular filtration.

Pontillo C, Jacobs L, Staessen JA, Schanstra JP, Rossing P, Heerspink HJL, Siwy J, Mullen W, Vlahou A, Mischak H, Vanholder R, Zürbig P, Jankowski J.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1510-1516. doi: 10.1093/ndt/gfw239.


Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression.

Pejchinovski M, Siwy J, Metzger J, Dakna M, Mischak H, Klein J, Jankowski V, Bae KT, Chapman AB, Kistler AD.

Nephrol Dial Transplant. 2017 Mar 1;32(3):487-497. doi: 10.1093/ndt/gfw243.


Proteomic Analysis of Vitreous Humor in Retinal Vein Occlusion.

Reich M, Dacheva I, Nobl M, Siwy J, Schanstra JP, Mullen W, Koch FH, Kopitz J, Kretz FT, Auffarth GU, Koss MJ.

PLoS One. 2016 Jun 30;11(6):e0158001. doi: 10.1371/journal.pone.0158001. eCollection 2016.


Proteomics of vitreous in neovascular age-related macular degeneration.

Nobl M, Reich M, Dacheva I, Siwy J, Mullen W, Schanstra JP, Choi CY, Kopitz J, Kretz FT, Auffarth GU, Koch F, Koss MJ.

Exp Eye Res. 2016 May;146:107-17. doi: 10.1016/j.exer.2016.01.001. Epub 2016 Jan 6.


Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.

Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R.

J Am Soc Nephrol. 2015 Aug;26(8):1999-2010. doi: 10.1681/ASN.2014050423. Epub 2015 Jan 14.


Pretransplant urinary proteome analysis does not predict development of chronic kidney disease after liver transplantation.

Milongo D, Bascands JL, Huart A, Esposito L, Breuil B, Moulos P, Siwy J, Ramírez-Torres A, Ribes D, Lavayssière L, Del Bello A, Muscari F, Alric L, Bureau C, Rostaing L, Schanstra JP, Kamar N.

Liver Int. 2015 Jul;35(7):1893-901. doi: 10.1111/liv.12763. Epub 2015 Jan 20.


Urinary proteomics in obstructive sleep apnoea and obesity.

Seetho IW, Siwy J, Albalat A, Mullen W, Mischak H, Parker RJ, Craig S, Duffy N, Hardy KJ, Burniston JG, Wilding JP.

Eur J Clin Invest. 2014 Nov;44(11):1104-15. doi: 10.1111/eci.12346.


Proteomics of vitreous humor of patients with exudative age-related macular degeneration.

Koss MJ, Hoffmann J, Nguyen N, Pfister M, Mischak H, Mullen W, Husi H, Rejdak R, Koch F, Jankowski J, Krueger K, Bertelmann T, Klein J, Schanstra JP, Siwy J.

PLoS One. 2014 May 14;9(5):e96895. doi: 10.1371/journal.pone.0096895. eCollection 2014.


Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.

Siwy J, Schanstra JP, Argiles A, Bakker SJ, Beige J, Boucek P, Brand K, Delles C, Duranton F, Fernandez-Fernandez B, Jankowski ML, Al Khatib M, Kunt T, Lajer M, Lichtinghagen R, Lindhardt M, Maahs DM, Mischak H, Mullen W, Navis G, Noutsou M, Ortiz A, Persson F, Petrie JR, Roob JM, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Snell-Bergeon J, Spasovski G, Stojceva-Taneva O, Trillini M, von der Leyen H, Winklhofer-Roob BM, Zürbig P, Jankowski J.

Nephrol Dial Transplant. 2014 Aug;29(8):1563-70. doi: 10.1093/ndt/gfu039. Epub 2014 Mar 2.


Capillary electrophoresis interfaced with a mass spectrometer (CE-MS): technical considerations and applicability for biomarker studies in animals.

Albalat A, Husi H, Siwy J, Nally JE, McLauglin M, Eckersall PD, Mullen W.

Curr Protein Pept Sci. 2014 Feb;15(1):23-35. Review.


Long term metabolic syndrome induced by a high fat high fructose diet leads to minimal renal injury in C57BL/6 mice.

Dissard R, Klein J, Caubet C, Breuil B, Siwy J, Hoffman J, Sicard L, Ducassé L, Rascalou S, Payre B, Buléon M, Mullen W, Mischak H, Tack I, Bascands JL, Buffin-Meyer B, Schanstra JP.

PLoS One. 2013 Oct 3;8(10):e76703. doi: 10.1371/journal.pone.0076703. eCollection 2013.


[Proteome-based diagnostic and prognostic biomarkers of prostate cancer].

Neuhaus J, Schiffer E, Siwy J, Mannello F, Horn LC, Stolzenburg JU.

Urologe A. 2013 Sep;52(9):1251-5. doi: 10.1007/s00120-013-3308-0. Review. German.


Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves (PUV).

Klein J, Lacroix C, Caubet C, Siwy J, Zürbig P, Dakna M, Muller F, Breuil B, Stalmach A, Mullen W, Mischak H, Bandin F, Monsarrat B, Bascands JL, Decramer S, Schanstra JP.

Sci Transl Med. 2013 Aug 14;5(198):198ra106. doi: 10.1126/scitranslmed.3005807.


Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment.

Albalat A, Stalmach A, Bitsika V, Siwy J, Schanstra JP, Petropoulos AD, Vlahou A, Jankowski J, Persson F, Rossing P, Jaskolla TW, Mischak H, Husi H.

Proteomics. 2013 Oct;13(20):2967-75. doi: 10.1002/pmic.201300100.


Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate Products.

Klein G, Schanstra JP, Hoffmann J, Mischak H, Siwy J, Zimmermann K.

PLoS One. 2013 Jun 19;8(6):e66682. doi: 10.1371/journal.pone.0066682. Print 2013.


Urine as a source for clinical proteome analysis: from discovery to clinical application.

Rodríguez-Suárez E, Siwy J, Zürbig P, Mischak H.

Biochim Biophys Acta. 2014 May;1844(5):884-98. doi: 10.1016/j.bbapap.2013.06.016. Epub 2013 Jul 2. Review.


Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.

Neuhaus J, Schiffer E, von Wilcke P, Bauer HW, Leung H, Siwy J, Ulrici W, Paasch U, Horn LC, Stolzenburg JU.

PLoS One. 2013 Jun 24;8(6):e67514. doi: 10.1371/journal.pone.0067514. Print 2013.


CKD273, a new proteomics classifier assessing CKD and its prognosis.

Argilés Á, Siwy J, Duranton F, Gayrard N, Dakna M, Lundin U, Osaba L, Delles C, Mourad G, Weinberger KM, Mischak H.

PLoS One. 2013 May 14;8(5):e62837. doi: 10.1371/journal.pone.0062837. Print 2013.


High-resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS.

Albalat A, Bitsika V, Zurbig P, Siwy J, Mullen W.

Methods Mol Biol. 2013;984:153-65. doi: 10.1007/978-1-62703-296-4_12.


Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.

Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, Mrug M, Grantham JJ, Bae KT, Bost JE, Mullen W, Wüthrich RP, Mischak H, Chapman AB.

PLoS One. 2013;8(1):e53016. doi: 10.1371/journal.pone.0053016. Epub 2013 Jan 10. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/9281c713-d253-4a1a-8255-92e691e77a24.


Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles.

Siwy J, Zoja C, Klein J, Benigni A, Mullen W, Mayer B, Mischak H, Jankowski J, Stevens R, Vlahou A, Kossida S, Perco P, Bahlmann FH.

PLoS One. 2012;7(12):e51334. doi: 10.1371/journal.pone.0051334. Epub 2012 Dec 7.


A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases.

Molin L, Seraglia R, Lapolla A, Ragazzi E, Gonzalez J, Vlahou A, Schanstra JP, Albalat A, Dakna M, Siwy J, Jankowski J, Bitsika V, Mischak H, Zürbig P, Traldi P.

J Proteomics. 2012 Oct 22;75(18):5888-97. doi: 10.1016/j.jprot.2012.07.024. Epub 2012 Jul 26.


Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat.

Rouse R, Siwy J, Mullen W, Mischak H, Metzger J, Hanig J.

PLoS One. 2012;7(4):e34606. doi: 10.1371/journal.pone.0034606. Epub 2012 Apr 11.


Performance of different separation methods interfaced in the same MS-reflection TOF detector: a comparison of performance between CE versus HPLC for biomarker analysis.

Mullen W, Albalat A, Gonzalez J, Zerefos P, Siwy J, Franke J, Mischak H.

Electrophoresis. 2012 Feb;33(4):567-74. doi: 10.1002/elps.201100415.


Urinary proteome analysis at 5-year followup of patients with nonoperated ureteropelvic junction obstruction suggests ongoing kidney remodeling.

Bandin F, Siwy J, Breuil B, Mischak H, Bascands JL, Decramer S, Schanstra JP.

J Urol. 2012 Mar;187(3):1006-11. doi: 10.1016/j.juro.2011.10.169. Epub 2012 Jan 20.


A pilot study on the effect of short-term consumption of a polyphenol rich drink on biomarkers of coronary artery disease defined by urinary proteomics.

Mullen W, Gonzalez J, Siwy J, Franke J, Sattar N, Mullan A, Roberts S, Delles C, Mischak H, Albalat A.

J Agric Food Chem. 2011 Dec 28;59(24):12850-7. doi: 10.1021/jf203369r. Epub 2011 Nov 28.


A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy.

Kistler AD, Siwy J, Breunig F, Jeevaratnam P, Scherl A, Mullen W, Warnock DG, Wanner C, Hughes DA, Mischak H, Wüthrich RP, Serra AL.

PLoS One. 2011;6(6):e20534. doi: 10.1371/journal.pone.0020534. Epub 2011 Jun 15.


Human urinary peptide database for multiple disease biomarker discovery.

Siwy J, Mullen W, Golovko I, Franke J, Zürbig P.

Proteomics Clin Appl. 2011 Jun;5(5-6):367-74. doi: 10.1002/prca.201000155. Epub 2011 May 18.


Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis.

Lankisch TO, Metzger J, Negm AA, Vosskuhl K, Schiffer E, Siwy J, Weismüller TJ, Schneider AS, Thedieck K, Baumeister R, Zürbig P, Weissinger EM, Manns MP, Mischak H, Wedemeyer J.

Hepatology. 2011 Mar;53(3):875-84. doi: 10.1002/hep.24103. Epub 2011 Jan 3.


Urinary proteomics for prediction of preeclampsia.

Carty DM, Siwy J, Brennand JE, Zürbig P, Mullen W, Franke J, McCulloch JW, Roberts CT, North RA, Chappell LC, Mischak H, Poston L, Dominiczak AF, Delles C.

Hypertension. 2011 Mar;57(3):561-9. doi: 10.1161/HYPERTENSIONAHA.110.164285. Epub 2011 Jan 3. Erratum in: Hypertension. 2011 Oct;58(4):e32. Roberts, Claire T [added].


Supplemental Content

Support Center